OSR (NASDAQ:OSRH – Get Free Report) is one of 89 public companies in the “UNCLASSIFIED” industry, but how does it weigh in compared to its peers? We will compare OSR to similar companies based on the strength of its dividends, profitability, earnings, institutional ownership, risk, valuation and analyst recommendations.
Risk & Volatility
OSR has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, OSR’s peers have a beta of -0.08, indicating that their average stock price is 108% less volatile than the S&P 500.
Earnings & Valuation
This table compares OSR and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| OSR | N/A | -$2.41 million | -0.51 |
| OSR Competitors | $41.37 million | -$18.54 million | 94.32 |
Profitability
This table compares OSR and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OSR | N/A | -6.66% | -4.90% |
| OSR Competitors | 0.86% | 0.95% | 0.80% |
Analyst Ratings
This is a breakdown of current ratings for OSR and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OSR | 1 | 0 | 0 | 0 | 1.00 |
| OSR Competitors | 231 | 266 | 217 | 3 | 1.99 |
As a group, “UNCLASSIFIED” companies have a potential upside of 101.09%. Given OSR’s peers stronger consensus rating and higher probable upside, analysts plainly believe OSR has less favorable growth aspects than its peers.
Insider and Institutional Ownership
55.3% of OSR shares are held by institutional investors. Comparatively, 52.0% of shares of all “UNCLASSIFIED” companies are held by institutional investors. 60.6% of OSR shares are held by insiders. Comparatively, 42.9% of shares of all “UNCLASSIFIED” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
OSR peers beat OSR on 9 of the 13 factors compared.
About OSR
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.
Receive News & Ratings for OSR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OSR and related companies with MarketBeat.com's FREE daily email newsletter.
